Skip to content

Carisma Therapeutics Inc.

CIK 0001485003

← back to feed
Revenue (TTM)
$61.6M
+31.5% YoY Q3 Nov 2025
Net Income (TTM)
$12.98M
+30.4% YoY Q3 Nov 2025
EPS Diluted (TTM)
$0.31
+43.6% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
25.3%
Q3 Nov 2025
Net Margin
21.1%
Q3 Nov 2025
Free Cash Flow (TTM)
−$24.58M
Q3 Nov 2025
Cash
$2.78M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
41.85M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings